Organisation mondiale de la santé (OMS) · Technical Documents

Polio Bulletin - 2016, Issue no. 04 (Week 7)

16 février 2016 Organisation mondiale de la santé

Le texte intégral est hébergé par l’organisation qui le publie. lawenc.com indexe les métadonnées et renvoie vers la source officielle.

Texte intégral

2016 Issue No. 4 - Week 7 (as of 16 February 2016) HIGHLIGHTS Meeting of the Polio Oversight Board On 13 January a regular meeting (via teleconference) of the Polio Oversight Board (POB) took place. The POB discussed the progress on the following items: Pakistan: The program priorities for the next six months include reducing the number of missed children and continuously improving the campaign performance. Political commitment and program oversight have been strengthened. The POB appreciated the work of polio staff under difficult circumstances and noted POB's commitment to help get Pakistan over the finish line. Afghanistan: Despite progress, inaccessible areas and cross border movements represent continuous challenges for the program. It was noted that insecurity was likely to be a major challenge moving forward. The POB and the Global Polio Eradication Initiative (GPEI) offered commitment and support to help Afghanistan address performance issues. Financial update: In the September 2015 meeting, the POB approved a $7 billion overall budget. Polio eradication activities for the first quarter of 2016 are fully funded. A comprehensive report on 2015 expenditures will be available by the end of March 2016. Resource mobilization: A donor strategy has been completed for all markets with donor maps and documents for key donors are being finalized. Provided that all current donors maintain their commitments, GPEI will be close to reach its fundraising targets. Routine immunization: The switch from trivalent to bivalent OPV is on track for 155 countries. Due to global supply constraints, 19 countries will be introducing inactivated polio vaccine (IPV) after the switch dates. The POB agreed to work with GAVI to strengthen immunization systems. Legacy planning: Multiple countries were identified as high priority for legacy planning activities as they have the most polio assets. The Legacy Management Group has a budget to support priority countries. The POB agreed to support high-level advocacy for legacy. See more at: http://www.polioeradication.org/Portals/0/Document/Aboutus/ Governance/POB/POB_Minutes_Mtg20160113.pdf 3.5

Polio Bulletin

Chart 1. Non-polio AFP rate (per 100 000 persons < 15 years of age), 2013–2015 100%

Chart 2. Adequate specimen collection rate, 2013–2015

3.0 80%

2.5 60%

2.0

1.5

40%

1.0 20%

0.5 0%

0.0 13 14 CHN 15 13 14 KHM 15 13 14 LAO 15 13 14 MYS 15 13 14 PHL 15 13 14 PNG 15 13 14 VNM 15

14 CHN

14 KHM

14 LAO

14 MYS

14 PHL

14 PNG

14 VNM

Chart 3. Percentage of reported AFP cases by number of polio vaccination doses, 2015 100%

Chart 4. Percentage of reported AFP cases with pending classification > 90 days after onset, 2015 CHN 5.4% 0.0% 31.4% 20.5% 8.0% 0.0% 6.8% 0% 5% 10% 15% 20% 25% 30% 35%

80%

KHM LAO MYS

60%

40%

PHL PNG VNM

20%

CONTACT US Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: +63 2 5288001 Fax: +63 2 5211036, 5260279 Email: WPR_EPIdata@wpro.who.int Web: www.wpro.who.int/immunization

0% CHN KHM LAO MYS 1-2 doses

PHL 0 doses

PNG Unknown

VNM

≥ 3 doses

Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People’s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).

Table 1A. Classification of AFP cases with onset in 2015 and key surveillance indicators 2014 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate % % with investigated adequate ≤ 2 days of specimens 2 notification 3 ≥ 80% ≥ 80% Latest report date 4 Days since last report 5

2015 Indicators

Country/area

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries and areas Total 1. 2. 3. 4. 5. 6.

60 4 72 5758 19 1 28 161 9 8 12 272 88 8 361 15 6876

44 1 46 2234 8 1 163 24 77 9 9 34 387 70 6 231 10 3354

57 3 84 5297 10 1 86 146 9 7 27 438 82 8 367 14 6636

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 7 6

0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1

41 2 84 4418 10 1 48 107 7 5 26 397 78 8 271 10 5513

16 1 0 878 0 0 31 39 2 2 1 41 4 0 96 4 1115

4 (7.0%) 0 (0.0%) 0 (0.0%) 287 (5.4%) 0 (0.0%) 0 (0.0%) 27 (31.4%) 30 (20.5%) 0 (0.0%) 2 (28.6%) 0 (0.0%) 35 (8.0%) 0 (0.0%) 0 (0.0%) 25 (6.8%) 3 (21.4%) 413 (6.2%) Green Yellow Red

1.30 3.00 1.83 2.37 1.25 1.00 3.58 1.90 1.00 0.78 0.79 1.13 1.17 1.33 1.59 1.40 1.98

25% 100% 99% 92% 80% 100% 51% 77% 100% 29% 30% 65% 85% 100% 96% 71% 89%

98% 100% 100% 100% 100% 100% 98% 64% 100% 100% 74% 97% 87% 88% 96% 100% 98%

29-Jan-16 06-Jan-16 01-Feb-16 11-Feb-16 04-Feb-16 15-Jan-16 16-Feb-16 16-Feb-16 04-Jan-16 06-Jan-16 12-Feb-16 11-Feb-16 15-Jan-16 03-Feb-16 06-Jan-16 26-Jan-16

18 41 5 0 0 43 41 4 5 32 41 21

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Report date is fixed as soon as all cases for the year have been classified Countries are expected to submit data at least once per month to WPRO Includes two cases that are 15 years old or older

Reached o r surpassed target Nearly reached target: 0.5–0.99 fo r no n-po lio A FP rate; 60–79% fo r o ther indicato rs Substantially belo w target

Polio Bulletin

Table 1B. Classification of AFP cases with onset in 2016 and key surveillance indicators 2015 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate 2 % % with investigated adequate ≤ 2 days of specimens 3 notification 4 ≥ 80% ≥ 80% Latest report date Days since last report 5

2016 Indicators

Country/area

Poliocompatible

Discarded (Non-polio)

Total

> 90 days 1 # (%)

≥1

≤ 30

57 3 84 5297 10 1 86 146 9 7 27 438 82 8 367 14 6636

45 1 46 2234 8 1 163 24 77 9 9 34 387 70 6 231 10 3355

1 0 3 128 0 0 17 6 0 0 2 19 0 0 0 0 176

0 0 0 0 0 0 0 0

0 0 0 2 0 0 0 2 6

0 0 0 0 0 0 0 0

0 3 3 6 0 0 0 12

1 0 125 9 6 2 19 162

0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Green Yellow Red

0.17 0.48 0.43 5.26 0.58 0.44 0.36 0.39

100% 100% 92% 71% 83% 100% 79% 89%

100% 100% 100% 94% 33% 100% 89% 96%

29-Jan-16 06-Jan-16 10-Feb-16 11-Feb-16 04-Feb-16 15-Jan-16 16-Feb-16 10-Feb-16 04-Jan-16 06-Jan-16 12-Feb-16 11-Feb-16 15-Jan-16 03-Feb-16 06-Jan-16 26-Jan-16

18 41 6 5 12 32 0 6 43 41 4 5 32 13 41 21

Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Annualized non-polio AFP rate per 100 000 population under 15 years of age Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases investigated within two days of notification Countries are expected to submit data at least once per month to WPRO Includes one case that is 15 years old or older

Reached o r surpassed target Nearly reached target: 0.5–0.99 fo r no n-po lio A FP rate; 60–79% fo r o ther indicato rs Substantially belo w target

Polio Bulletin

Table 2A. Laboratory investigation of stool samples from AFP cases with onset in 2015 and key laboratory indicators Results of virus isolation for AFP cases Country/area Polio laboratory Total no. of AFP cases with specimens L20B positive L20B positive + NPEV only NPEV % results % reported specimens Pending Latest Pending 14 days ≤ ≤ 14 days > 14 days positive for report date NPEV ≥ 80% Intratypic differentiation/ Sequencing 1 laboratory No. of isolates received Type 1 W ild Sabin VDPV Results of intratypic differentiation (ITD)/sequencing for virus isolates Type 2 Type 3 W ild Sabin VDPV W ild Sabin VDPV NPEV 2 1

Negative

Pending ITD

% ITD results Discordant reported ≤ 7 pending days of sequencing receipt ≥ 80%

Australia Brunei Darussalam Cambodia China (total) China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet China, Hong Kong SAR China, Macao SAR Japan Lao People's Democratic Republic Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam (North) Viet Nam (South) Pacific island countries and areas Total

VIDRL VIDRL NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC NIID NIID IMR PHI IESR VIDRL RITM NIH SGH NIHE PI VIDRL

45 3 84 5240 305 30 158 103 359 280 303 129 503 295 233 177 51 98 369 39 140 364 42 119 217 186 80 215 39 181 90 90 24 19 2 10 0 75 147 9 4 25 480 82 8 211 175 15 6613

0 0 1 68 2 3 4 0 9 3 6 1 8 1 4 6 0 1 1 0 0 1 1 3 7 3 1 0 0 1 0 2 0 0 0 0 10 0 0 0 1 4 0 0 3 0 1 88

0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 3

4 0 10 466 18 0 25 12 13 39 58 5 48 32 4 4 5 5 34 1 12 25 0 16 21 18 8 27 3 22 5 3 1 2 0 0 7 11 2 0 6 60 8 1 20 17 3 615

40 2 73 4647 262 27 129 90 336 225 238 123 445 258 224 167 46 89 332 38 128 334 41 100 187 165 69 188 36 158 85 85 23 17 2 10 56 136 7 4 18 414 72 7 188 158 11 5843

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 0 0 0 0 4

1 1 0 58 23 0 0 1 1 13 0 0 2 4 1 0 0 3 2 0 0 4 0 0 2 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 60

95% 100% 96% 96% 97% 98% 99% 97% 97% 99% 99% 100% 90% 98% 99% 100% 98% 96% 98% 100% 91% 94% 100% 97% 93% 95% 99% 99% 90% 96% 97% 98% 98% 100% 100% 84% 99% 98% 94% 100% 95% 90% 89% 100% 99% 98% 93% 95%

5% 0% 11% 8% 5% 0% 15% 9% 3% 12% 15% 4% 7% 10% 2% 2% 7% 4% 7% 3% 8% 6% 0% 13% 9% 8% 7% 11% 6% 12% 4% 2% 2% 11% 0% 0% 10% 5% 22% 0% 21% 10% 9% 6% 9% 10% 18% 8%

01-Feb-16 01-Feb-16 14-Jan-16 11-Feb-16

VIDRL VIDRL NIID Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC

0 0 0 177 4 10 11 0 31 6 10 1 16 2 6 12 0 2 1 4 0 5 2 6 16 10 3 2 2 4 2 5 4 0 0 0 0 18 0 0 0 1 9 0 0 7 0 2 214

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

52 1 3 0 4 0 7 0 11 0 2 6 2 0 2 0 0 2 6 2 0 2 0 2 0 0 0 5 1 1 4 0 63

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 6 0 0 0 0 7

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

61 1 4 7 14 2 3 0 1 2 2 4 0 1 2 2 0 4 4 4 0 0 2 0 0 2 0 2 0 2 2 0 67

7 0 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 7

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

54 2 3 4 8 4 0 1 4 0 2 2 0 0 0 3 2 0 6 1 3 0 0 2 0 3 4 5 0 6 0 2 67

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 1 0 3

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

98% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 86% 100% 67% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 98%

19-Jan-16 19-Jan-16 06-Feb-16 11-Feb-16 11-Jan-16 20-Jan-16 01-Feb-16 09-Feb-16 15-Jan-16 15-Jan-16 12-Jan-16 16-Feb-16 01-Feb-16

PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

1. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, China, Hong Kong SAR); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. NPEV growing in L20B cells

Polio Bulletin

Table 2B. Laboratory investigation of stool samples from AFP cases with onset in 2016 and key laboratory indicators Results of virus isolation for AFP cases Country/area Polio laboratory Total no. of AFP cases w ith specimens L20B positive L20B positive + NPEV only NPEV % results % reported specimens Pending Latest Pending 14 days ≤ ≤ 14 days > 14 days positive for report date NPEV ≥ 80% Intratypic differentiation/ Sequencing 1 laboratory No. of isolates received Type 1 W ild Sabin VDPV Results of intratypic differentiation (ITD)/sequencing for virus isolates Type 2 Type 3 W ild Sabin VDPV W ild Sabin VDPV NPEV 2 1

Negative

Pending ITD

% ITD results Discordant reported ≤ 7 pending days of sequencing receipt ≥ 80%

2 0 3 124 5 2 3 2 16 7 4 2 9 4 5 4 1 4 10 0 1 10 1 0 5 7 3 5 3 6 1 3 1 0 0 0 0 12 17 0 0 1 23 0 0 0 5 2 189

0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 5

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 2 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 1 2 0 6

1 3 99 5 2 3 2 15 6 3 2 8 3 2 4 1 3 6 0 6 1 2 7 3 2 2 6 1 3 1 7 17 1 18 3 1 150

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 1 6

0 0 22 0 0 0 0 1 1 1 0 0 1 3 0 0 1 4 1 3 0 3 0 0 3 0 0 0 0 0 0 0 0 0 0 0 22

100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 91% 100% 100% 82% 100% 100% 100%

0% 0% 2% 0% 0% 0% 0% 0% 0% 0% 0% 6% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 33% 0% 0% 0% 0% 9% 0% 0% 6% 40% 0% 2%

12-Feb-16 12-Feb-16 08-Feb-16 11-Feb-16

0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 10

0 0 0 0

0 0 2 2

0 0 4 4

0 0 0 0

3 3 1 4

0 0 0 0

100% 100% 100% 100%

Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC

Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC

19-Jan-16 19-Jan-16 15-Feb-16 11-Feb-16 11-Jan-16 01-Feb-16 12-Feb-16 09-Feb-16 15-Jan-16 12-Feb-16 12-Jan-16 16-Feb-16 12-Feb-16

CCDC CCDC PHLC PHLC NIID NIID IMR NIID IESR VIDRL RITM NIH SGH NIHE PI VIDRL

Polio Bulletin

Table 3. Laboratory confirmation of polio isolates from environmental samples in 2014–2015 1 2014 Country/area Intratypic differentiation lab 2 Total number of samples processed Total number of samples with polio isolates Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin VDPV Discordant Total number Pending pending NPEV of samples ITD sequencing processed Total number of samples with polio isolates Type 1 Wild Sabin VDPV Wild

2015 Type 2 Sabin VDPV Wild Type 3 NPEV Sabin VDPV Pending ITD Discordant pending sequencing

Australia China (total) 3

VIDRL Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC Prov. Lab/CCDC IMR

3 167 14 0 48 0 18 48 12 27 0 21 191

0 167 14 0 48 0 18 48 12 27 0 7 174

0 0 0 0 0 0 0 0 0

79 1 21 11 13 6 27 1 80

0 0 0 0 0 0 0 0 0

129 4 22 37 16 12 38 1 130

2 0 0 1 0 0 1 0 2

0 0 0 0 0 0 0 0 0

115 0 15 47 23 10 20 5 120

0 0 0 0 0 0 0 0 0

3 0 0 0 0 0 0 0 7 10

0 0 0 0 0 0 0 0 0 0

29 1486 77 88 171 261 47 305 129 396 12 0 1515

2 630 13 46 43 71 20 108 21 308 0 632

0 0 0 0 0 0 0 0 0 0 0 0

0 193 0 11 11 10 2 43 2 114 0 193

0 0 0 0 0 0 0 0 0 0 0 0

1 243 12 9 24 12 16 25 12 133 0 244

0 1 0 0 1 0 0 0 0 0 0 1

0 0 0 0 0 0 0 0 0 0 0 0

1 274 1 28 7 52 2 40 7 137 0 275

0 0 0 0 0 0 0 0 0 0 0 0

26 851 64 37 128 190 27 197 108 88 12 877

0 5 0 5 0 0 0 0 0 0 0 5

0 35 0 0 0 0 0 0 0 35 0 35

China, Fujian China, Gansu China, Guangdong China, Guangxi China, Heilongjiang China, Shandong China, Shanghai China, Xinjiang China, Yunnan Malaysia Total

1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IMR (Institute of Medical Research, Malaysia); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 3. Reported data from China are currently being verified and may be amended in the next issue of the bulletin.

Table 4. Vaccine-derived poliovirus identified from laboratory testing2, 2000-2016 Country/area Cambodia

2000–2009 2006 - 1 Total - 2 2009 - 1 Total - 27

2010

2011

2012

2013

2014

2015

2016

China

aVDPV2 (3 AFP + 1 contact + 1 non-AFP) aVDPV3 (1 AFP + 1 non-AFP)

aVDPV1 (1 AFP) aVDPV2 (2 AFP + 1 contact) cVDPV2 (1 AFP + 1 non-AFP) iVDPV2 (1 AFP + 1 non-AFP) iVDPV3 (1 AFP)

aVDPV1 (1 AFP) aVDPV2 (2 AFP) cVDPV2 (2 AFP + 1 contact) iVDPV2 + iVDPV3 (1 AFP)

aVDPV2 (1 non-AFP) iVDPV2 + iVDPV3 (1 AFP)

aVDPV1 (1 non-AFP) aVDPV2 (2 AFP) iVDPV3 (1 AFP)

aVDPV1 (1 AFP) aVDPV2 (1 AFP) iVDPV2 (1 AFP)

China, Hong Kong SAR Japan Lao People's Democratic Republic Mongolia Philippines Viet Nam

2005 - 3 2005 - 1 Total - 2 2004 - 3 2003 - 1 2001 - 3 aVDPV2 (2 AFP) aVDPV2 (1 AFP) cVDPV1 (7 AFP + 20 contacts) cVDPV1 (2 AFP + 3 contacts)

1. Prefix letter refers to the VDPV category: "cVDPV" = circulating VDPV, "iVDPV" = immunodeficiency-associated VDPV, "aVDPV" = ambiguous VDPV, "?VDPV" = pending. Suffix number refers to the poliovirus serotype (types 1, 2 or 3). 2. Source of specimens could be AFP cases, contacts, or non-AFP cases 3. Refers to year of last VDPV case, and aggregate total of VDPV cases for 2000-2009

Polio Bulletin

Informations clés

Organisation Organisation mondiale de la santé (OMS)

Type de document Technical Documents

Date d'adoption 16 février 2016

Source Organisation mondiale de la santé